March 26th 2023
The gynecological cancer lymphedema questionnaire and the lower extremity lymphedema screening questionnaire showed moderate to substantial agreement across different cutoff points.
February 27th 2023
Kathryn Maples, PharmD, BCOP, discusses recent approvals, updated labeling, and drug removals across leukemia, lymphoma, and multiple myeloma.
February 20th 2023
The efficacy profile for avelumab in patients with locally advanced or metastatic urothelial carcinoma was consistent in a real-world setting with what had been reported in the phase 3 JAVELIN Bladder 100 trial.
February 7th 2023
An economic analysis showed that neither polatuzumab vedotin-piiq added to standard of care chemotherapy nor CD19-directed chimeric antigen receptor T-cell therapy is likely to be the most cost-effective for patients with diffuse large B-cell lymphoma.
January 23rd 2023
The high concordance rate between gastric and breast cancer HER2 scoring algorithms suggest that either may be used in the metastatic colorectal cancer setting.
January 20th 2023
In the first-line treatment of patients with advanced hepatocellular carcinoma, a combination of pembrolizumab plus lenvatinib yielded similar health-related quality of life scores as lenvatinib plus placebo, according to a HRQOL analysis of the phase 3 LEAP-002 study.
January 10th 2023
Treatment with adjuvant pembrolizumab resulted in favorable quality-of-life outcomes vs high-dose interferon α 2b or ipilimumab in patients with resected melanoma at high risk for relapse.
January 9th 2023
Patients with stage III colon cancer who receive longer courses of adjuvant oxaliplatin, exercise for less than 9 hours per week, have diabetes, or have a higher body mass index could experience higher rates of severe oxaliplatin-induced peripheral neuropathy.
December 11th 2022
Daratumumab in addition to bortezomib, lenalidomide, and dexamethasone induction/consolidation therapy, as well as with lenalidomide maintenance, showcased a promising health-related quality of life benefit for patients with transplant eligible, newly diagnosed multiple myeloma.
December 7th 2022
Neoadjuvant treatment with trastuzumab deruxtecan showed promising responses in patients with early-stage breast cancer.
November 26th 2022
Increasing the duration of bevacizumab treatment in the frontline setting did not improve progression-free survival for patients with advanced ovarian cancer.
November 25th 2022
Almost single-handedly, Jennifer Temel, MD, defined a research field in medicine, creating a new focus on quality of life for patients and survivors.
November 21st 2022
The median time between pathologic diagnosis to next-generation sequencing was reduced in a quality improvement project for patients with newly diagnosed metastatic non–small cell lung cancer.
November 6th 2022
Kiran Virdee, RN, BSN, CCRN-K, outlines the best practices for the management of adverse effects during the treatment of kidney cancer.
October 21st 2022
The combination of encorafenib and binimetinib led to sustained improvements in progression-free survival and overall survival, without new safety signals in patients with BRAF V600–mutant melanoma, according to 5-year follow-up of the phase 3 COLUMBUS trial.
October 14th 2022
Dual inhibition with letrozole and abemaciclib displayed response and survival benefits in patients with recurrent estrogen receptor–positive endometrioid endometrial cancer.
October 7th 2022
Luspatercept produced favorable safety and long-term efficacy in patients with untreated lower-risk myelodysplastic syndromes, irrespective of subtype.
September 26th 2022
Intensity-modulated radiation therapy elicited durable efficacy and a favorable safety profile compared with conventional radiotherapy in patients with endometrial and cervical cancers who received postoperative pelvic radiation.
September 12th 2022
An analysis of patient-reported outcomes from the phase 2 KEYNOTE-522 trial demonstrated that pembrolizumab was not associated with effects on health-related quality of life in patients with triple-negative breast cancer.
September 11th 2022
Trastuzumab deruxtecan demonstrated a promising quality-of-life benefit for patients with hormone receptor–positive, HER2-low metastatic breast cancer, according to a report on patient-reported outcomes from the pivotal DESTINY-Breast04 trial.